Navigation Links
HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Date:11/5/2007

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. This Phase 2b study demonstrated that, with half as many injections as Pegasys (peginterferon alfa 2a), Albuferon was just as effective in achieving sustained virologic response (SVR) an undetectable amount of virus in the blood at 24 weeks following the end of treatment with comparable safety and less impairment of health-related quality of life on treatment. Albuferon is administered every two weeks, while peginterferon alfa-2a requires administration every week.

The final Phase 2b data are being presented this week at the 58 th AASLD Annual Meeting in Boston. In two additional press releases also issued by HGS today, the Company announced the full presentations at AASLD of quality-of-life data from the Phase 2b trial, and results from the Phase 2 trial of Albuferon in combination with ribavirin in patients with chronic hepatitis C who had not responded to previous interferon-based treatment regimens.

The final Phase 2b results suggest that the every-two-week dosing regimen of Albuferon halves the number of injections that are required with peginterferon alfa-2a, while providing at least comparable efficacy, comparable safety and the potential for less impairment of quality of life and daily activity, said Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany. We are continuing the evaluation of the 900-mcg and 1200-mcg doses of Albuferon in larger populations in Phase 3 trials. We also conclude that monthly dosing of Albuferon deserves further evaluation.

In the open-label, multi-center, active-controlled Phase 2b trial, 458 treatment-naive patients with
'/>"/>

Contact: Jerry Parrott
301-315-2777
Edelman Public Relations
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ass., Jan. 8 CrossTech Forums toda...ght , the only national invitational summit featur...ights, an IDC company, will now take place at the ...l 29-May 1, 2009. Originally scheduled for January...four-diamond Phoenix resort in order to accommodat...
(Date:1/8/2009)..., N.J., Jan. 8 Pharmasse...t will present at the 27th Annual JPMorgan Healthc...009 at the Westin St Francis in San Francisco, CA....Executive Officer, will provide an overview of the..., 2009 at 9:00 AM (PT). , , To access a simult...
(Date:1/8/2009)...GO and GREENSBURG, Pa., Jan. 8 /PRNewswire-FirstCa...lth, a non-profit health care network serving,Wes...erprise Electronic Health,Record (EHR) for the mo...alth,Physician Practices (EHPP). , (Logo: ...041LOGO ) , Excela Health, serving residen...
(Date:1/8/2009)...19 Session in Orlando Will Feature Strategies ...Loyalty and Plan Profitability , , WOBURN, Mas...marketplace disruption - ranging from the employme...onsumer autonomy in health insurance selection - t...mbers is now a priority for the nation,s health in...
Breaking Medicine News(10 mins):Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 2Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 3Health News:Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference 2Health News:Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference 3Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 2Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 3Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 4Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 5Health News:World Health Care Congress and ConnextionsHealth Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 2Health News:World Health Care Congress and ConnextionsHealth Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 3
...tant TB could create an "apocalyptic scenario" if ...n 30,000 people.. The new plan from WHO and the S...eeded to slow the spread of multi-drug resistant T... or XDR-TB. The new plan will cost 2.5 billion as ...
...er this month whether internet and video game addi... the issue at the AMA national meeting at Chicago....oling up in their rooms, ignoring friends, family,..., while grades plummet and belligerence soars. Vid...
...s could be the difference between living or dying ...ch indicates . A study published in the online edi...d that omega-3 fatty acids found in the foods may ...isposition to the condition. Working with mice gen...
...nts higher, on average, than their younger sibling...s that its how the kids are raised, not their birt...esearchers who authored the report, published in t...he investigators found that children raised as the...
Other Medicine News:Health News:Plan to Contain Drug Resistant TB Launched-WHO 2Health News:Video Game Addiction to Be Termed as a Medical Condition 2Health News:First-borns Have Higher IQs Than Their Younger Siblings 2
(Date:1/5/2009)..., SAN DIEGO, Jan. 5 Cylene Pharm... Phase I clinical trial of its oral CK2 protein ki... solid tumors, Castleman,s disease, or multiple my...lating trial are determination of safety, toleranc...ppropriate dose for Phase II trials. In addition, ...
(Date:1/5/2009)..., SAN JOSE, Calif., Jan. 5 W...ire progesterone medication to help support early,...ome forms of this medication,can be painful for p...which,can be administered by subcutaneous injecti...ts with better patient tolerance. , With pa...
(Date:12/30/2008)..., WASHINGTON, Dec. 30 ...opposes the citizen petition filed by Genentech, I...bility of laboratories to offer diagnostic tests t...innovation in laboratory tests, would harm patient...mises. , , The Coalition,s mission is to encour...
(Date:12/27/2008)..., ST. DAVID,S, Bermuda, Dec. 23 /PRNewswire-Firs...) announced today that one of its subsidiaries and... subsidiary of Hospira, Inc., have filed lawsuits .... ("Mutual"), Mylan Pharmaceuticals Inc. ("Mylan")...strict Court for the District of New Jersey for in...
Breaking Medicine Technology:Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Earliest animal footprints ever found discovered in Nevada 5224 1Earliest animal footprints ever found discovered in Nevada 5224 2Earliest animal footprints ever found discovered in Nevada 5224 3Corner stores capture kids on morning commute 27015 1Corner stores capture kids on morning commute 27015 2Duke researchers show reading can help obese kids lose weight 27013 1Duke researchers show reading can help obese kids lose weight 27013 2Kount Lands Veteran Fraud Experts From Retail Decisions and iovation 5222 1Kount Lands Veteran Fraud Experts From Retail Decisions and iovation 5222 2
...HESDA, Md., March 29, 2007--For depressed people w...zer, adding an antidepressant,medication is no mor... to results published online on March 28, 2007 in ...re part of the,large-scale, multi-site Systematic ... (STEP-BD), a $26.8 million clinical trial,funded ...
...ot Study Demonstrates 50% Survival in Valortim-Tre... March 29, 2007 - Medarex,Inc. (Nasdaq: MEDX), a ...ne, Inc., a privately held biotechnology company d...easures, today announced,that Valortim, a fully hu...veloped for the prevention and treatment of anthra...
Other Medicine Technology:Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 2Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility :
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility :
GENTAMICIN SULFATE, 1000X
Gentamicin Sulphate : Antibiotic that inhibits normal protein synthesis. USBio analysed. Autoclavable.
Medicine Products: